CurveBeam AI (ASX:CVB) signed a commercial agreement with medical device manufacturer Stryker Australia for the Australia and New Zealand markets, according to a Tuesday filing with the Australian bourse.
Stryker will educate surgeons and promote the company's weight-bearing computed tomography imaging device HiRise for use in lower extremity orthopedic applications under the deal, the filing said.
The agreement, with an initial term of three years and a further term of two years, requires minimum referral volumes for sales and commissions to continue, per the filing.
CurveBeam AI shares were down 4% in afternoon trade Friday.
Price (AUD): $0.11, Change: $-0.0050, Percent Change: -4.35%
Comments